BioCentury
ARTICLE | Finance

Back to the bone

Why OrbiMed's Stephen Squinto is buying back into bone biology

October 5, 2015 7:00 AM UTC

In one of his first investments since joining OrbiMed Advisors in January, Stephen Squinto is returning to a space he knows well - biologics for an Orphan bone disease. The result was OrbiMed leading last week's $35 million series A round for Therachon.

New Enterprise Associates also participated and joined seed investors Inserm Transfert Initiative and Versant Ventures. ...